Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart L Fine

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|April 30, 2011
Ranibizumab and bevacizumab for neovascular age-related macular degeneration, Daniel F Martin, Maureen G Maguire, et al.
Retina (Philadelphia, Pa.)|November 29, 2013
Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and preventionRaul Velez-Montoya, Scott C N Oliver, Jeffrey L Olson, et al.
American Journal of Ophthalmology|June 21, 2014
Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)Dina Y Gewaily, Juan E Grunwald, Maxwell Pistilli, et al.
Ophthalmology|May 5, 2012
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Daniel F Martin, Maureen G Maguire, et al.
Ophthalmology|March 24, 2020
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results, , Daniel F Martin, et al.
Ophthalmology|May 10, 2016
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials, Maureen G Maguire, Daniel F Martin, et al.
Ophthalmology|December 10, 2013
Risk of scar in the comparison of age-related macular degeneration treatments trialsEbenezer Daniel, Cynthia A Toth, Juan E Grunwald, et al.
Ophthalmology|February 19, 2018
Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments TrialsEbenezer Daniel, Wei Pan, Gui-Shuang Ying, et al.
Ophthalmology|October 14, 2014
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)Michael M Altaweel, Ebenezer Daniel, Daniel F Martin, et al.
Ophthalmology|October 3, 2013
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trialsJuan E Grunwald, Ebenezer Daniel, Jiayan Huang, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|April 30, 2011
Ranibizumab and bevacizumab for neovascular age-related macular degeneration, Daniel F Martin, Maureen G Maguire, et al.
Retina (Philadelphia, Pa.)|November 29, 2013
Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and preventionRaul Velez-Montoya, Scott C N Oliver, Jeffrey L Olson, et al.
American Journal of Ophthalmology|June 21, 2014
Delayed patchy choroidal filling in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)Dina Y Gewaily, Juan E Grunwald, Maxwell Pistilli, et al.
Ophthalmology|May 5, 2012
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Daniel F Martin, Maureen G Maguire, et al.
Ophthalmology|March 24, 2020
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results, , Daniel F Martin, et al.
Ophthalmology|May 10, 2016
Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials, Maureen G Maguire, Daniel F Martin, et al.
Ophthalmology|December 10, 2013
Risk of scar in the comparison of age-related macular degeneration treatments trialsEbenezer Daniel, Cynthia A Toth, Juan E Grunwald, et al.
Ophthalmology|February 19, 2018
Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments TrialsEbenezer Daniel, Wei Pan, Gui-Shuang Ying, et al.
Ophthalmology|October 14, 2014
Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)Michael M Altaweel, Ebenezer Daniel, Daniel F Martin, et al.
Ophthalmology|October 3, 2013
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trialsJuan E Grunwald, Ebenezer Daniel, Jiayan Huang, et al.
Pageof 4